- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01164137
Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care (CMR)
12. februar 2013 opdateret af: Westview Physician Collaborative
Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care: to Develop and Test a Community-based Medication Reconciliation Program and a Risk Prediction Model That Identifies High-risk Patient Groups
This initiative aims to decrease the risk of medication errors at the hospital-community interface as well as health system utilization following hospital discharge by implementing a pharmacist-led medication reconciliation in the patients' home within 72 hours of hospital discharge.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The goals of this initiative are to decrease the risk for medication errors at the hospital community interface of care, thus decreasing preventable adverse drug events and preventable drug-related health system utilization following hospital discharge. This initiative has four objectives that aim to:
- Develop and test a community-based medication reconciliation process/intervention.
- Design and conduct a randomized controlled trial to examine the impact of the intervention on post-discharge health services utilization by comparing a set of outcome variables between intervention and non-intervention groups.
- Design a risk prediction model that helps identify patients discharged from in-patient care with the highest level of need for the intervention.
- Determine whether a community-based medication reconciliation process/intervention adds risk reduction value to individuals who have undergone an in-hospital medication reconciliation.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
156
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Alberta
-
Stony Plain, Alberta, Canada, T7Z 2M7
- Westview Health Centre
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Patients attending the WestView Health Centre Medicine/Family Health Unit with at least one medication at discharge.
Exclusion Criteria:
- First Nations persons
- Residents of continuing care or assisted living facilities
- Persons not residing in the Edmonton, AB, Canada region
- Persons who obtain a score of 19 or less on the Mini Mental State Examination (MMSE)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Medication Reconciliation Intervention
Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
|
A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
|
|
Ingen indgriben: Medication Reconciliation Non-Interven.
Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Health Services Utilization 3 Months Following Hospital Discharge
Tidsramme: 3 Months
|
Mean health services utilization 3 months following hospital discharge.
The specific health services utilization was re-admission to hospital, admission to home care, admission to long-term care and visits to emergency departments.
|
3 Months
|
|
Health Services Utilization 6 Months Following Hospital Discharge
Tidsramme: 6 Months
|
Mean health services utilization 6 months following hospital discharge.
The specific health services utilization was re-admission to hospital, admission to home care, admission to long-term care and visits to emergency departments.
|
6 Months
|
|
Health Services Utilization 9 Months Following Hospital Discharge
Tidsramme: 9 Months
|
Mean health services utilization 9 months following hospital discharge.
The specific health services utilization was re-admission to hospital, admission to home care, admission to long-term care and visits to emergency departments.
|
9 Months
|
|
Health Services Utilization 12 Months Following Hospital Discharge
Tidsramme: 12 months
|
Mean health services utilization 12 months following hospital discharge.
The specific health services utilization was re-admission to hospital, admission to home care, admission to long-term care and visits to emergency departments.
|
12 months
|
|
Health Services Utilization 18 Months Following Hospital Discharge
Tidsramme: 18 months
|
Mean health services utilization 18 months following hospital discharge.
The specific health services utilization was re-admission to hospital, admission to home care, admission to long-term care and visits to emergency departments.
|
18 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Allan Bailey, M.D., Westview Physician Collaborative
- Studieleder: Grace Moe, M.Sc.P.T., WestView Primary Care Network
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. november 2008
Primær færdiggørelse (Faktiske)
1. februar 2013
Studieafslutning (Faktiske)
1. februar 2013
Datoer for studieregistrering
Først indsendt
14. juli 2010
Først indsendt, der opfyldte QC-kriterier
15. juli 2010
Først opslået (Skøn)
16. juli 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
15. februar 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
12. februar 2013
Sidst verificeret
1. februar 2013
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CMPA#2026
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Uønskede lægemiddelhændelser
-
Onconic Therapeutics Inc.Rekruttering
-
Seoul National University Bundang HospitalAktiv, ikke rekrutterendeDrug Drug Interaction (DDI)Sydkorea
-
Theravance BiopharmaAfsluttet
-
National Taiwan Normal UniversityRekrutteringFysisk kondition | Event-relaterede potentialer | Eksekutiv funktion (kognition)Taiwan
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Drug-Drug Interaction (DDI)Det Forenede Kongerige
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Farmakokinetik | Drug-Drug Interaction (DDI)Tyskland
-
Beijing Union Pharmaceutical Factory LtdIkke rekrutterer endnuDrug Drug Interaction (DDI)Kina
-
SPARK BiopharmaAfsluttetDrug Drug Interaction (DDI)Sydkorea
-
Allyx TherapeuticsNational Institute on Aging (NIA)Aktiv, ikke rekrutterendeDrug Drug Interaction (DDI)Forenede Stater
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Farmakokinetik | Drug-Drug Interaction (DDI)Tyskland
Kliniske forsøg med Medication Reconciliation
-
VA Office of Research and DevelopmentIcahn School of Medicine at Mount Sinai; Weill Medical College of Cornell... og andre samarbejdspartnereAfsluttet
-
Leiden University Medical CenterRWTH Aachen University; University of Patras; University of LjubljanaRekrutteringPolyfarmaciTyskland, Grækenland, Slovenien
-
University of North Carolina, Chapel HillMedical University of South Carolina; National Institute of Mental Health... og andre samarbejdspartnereAfsluttetHIV/AIDS | Medicinadhærens | Hiv | Seksuel adfærd | Seksuelt overførte infektioner (ikke hiv eller hepatitis)Forenede Stater
-
University of MalayaIkke rekrutterer endnuForhøjet blodtryk | Dyslipidæmi | Diabetes mellitus type 2Malaysia
-
PHCC LPNational Heart, Lung, and Blood Institute (NHLBI)AfsluttetHjerte-kar-sygdommeForenede Stater
-
Fondazione Poliambulanza Istituto OspedalieroUkendtMedicineringsfejl og andre produktbrugsfejl og -problemer | BivirkningshændelseItalien
-
University of Wisconsin, MilwaukeeAfsluttetKronisk sygdom | Medicinadhærens
-
University of PittsburghTrukket tilbageMedicinadhærens | Bivirkninger på lægemiddel | Medicinsk manglende overholdelseForenede Stater
-
University Hospital, ToulouseAfsluttet
-
Fundació Sant Joan de DéuParc Sanitari Sant Joan de Déu; Institut Català de la Salut; Jordi Gol i... og andre samarbejdspartnereAfsluttetOverholdelse, MedicinSpanien